{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:15:30Z","timestamp":1766182530793,"version":"3.48.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jfma.2025.10.044","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:45:33Z","timestamp":1762947933000},"page":"S123-S129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S2","title":["Micro-elimination of hepatitis C in patients with chronic kidney disease and diabetes in Taiwan"],"prefix":"10.1016","volume":"124","author":[{"given":"Kuo-Chin","family":"Chang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1091-387X","authenticated-orcid":false,"given":"Yen-Po","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiou-Shiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Ling","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2659-4217","authenticated-orcid":false,"given":"Lay","family":"San Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yo-Yu","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Chuen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Chun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Chao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Nan","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-1956","authenticated-orcid":false,"given":"Chien-Te","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Hsiu-Hsi Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2017","series-title":"Global hepatitis report 2017","author":"Organization","key":"10.1016\/j.jfma.2025.10.044_bib1"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.044_bib2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.jfma.2018.10.021","article-title":"Achieving hepatitis C elimination in Taiwan-overcoming barriers by setting feasible strategies","volume":"117","author":"Wu","year":"2018","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jfma.2025.10.044_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jhep.2017.06.033","article-title":"Micro-elimination - a path to global elimination of hepatitis C","volume":"67","author":"Lazarus","year":"2017","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.044_bib4","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.drugpo.2015.07.010","article-title":"Defining populations and injecting parameters among people who inject drugs: implications for the assessment of hepatitis C treatment programs","volume":"26","author":"Larney","year":"2015","journal-title":"Int J Drug Pol"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.044_bib5","doi-asserted-by":"crossref","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","article-title":"Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review","volume":"5","author":"Degenhardt","year":"2017","journal-title":"Lancet Global Health"},{"issue":"8","key":"10.1016\/j.jfma.2025.10.044_bib6","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jiph.2023.05.019","article-title":"A new collaborative care approach toward hepatitis C elimination in marginalized populations","volume":"16","author":"Su","year":"2023","journal-title":"J Infect Public Health"},{"issue":"1 Suppl","key":"10.1016\/j.jfma.2025.10.044_bib7","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","article-title":"Epidemiology of viral hepatitis and HIV co-infection","volume":"44","author":"Alter","year":"2006","journal-title":"J Hepatol"},{"issue":"1\u20132","key":"10.1016\/j.jfma.2025.10.044_bib8","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2013.01.020","article-title":"Is the HCV-HIV co-infection prevalence amongst injecting drug users a marker for the level of sexual and injection related HIV transmission?","volume":"132","author":"Vickerman","year":"2013","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.044_bib9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.ajkd.2021.03.017","article-title":"Elimination of hepatitis C virus in a dialysis population: a collaborative care model in Taiwan","volume":"78","author":"Hu","year":"2021","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.044_bib10","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1136\/gutjnl-2020-323277","article-title":"Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C)","volume":"70","author":"Yu","year":"2021","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.044_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.14309\/ajg.0000000000002624","article-title":"Using the diabetes care system for a county-wide hepatitis C elimination: an integrated community-based shared care model in Taiwan","volume":"119","author":"Hu","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.jfma.2025.10.044_bib12","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJMra2033539","article-title":"Extrahepatic manifestations of chronic HCV infection","volume":"384","author":"Cacoub","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib13","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1186\/s12889-025-21851-z","article-title":"Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the global Burden of Disease Study 2021","volume":"25","author":"Deng","year":"2025","journal-title":"BMC Public Health"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.044_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.jfma.2025.10.044_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2369-14-187","article-title":"Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.044_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease - a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.044_bib17","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/hep.1840360621","article-title":"Extrahepatic manifestations of hepatitis C among United States male veterans","volume":"36","author":"El-Serag","year":"2002","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jfma.2025.10.044_bib18","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfn406","article-title":"Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance","volume":"23","author":"Yang","year":"2008","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"10.1016\/j.jfma.2025.10.044_bib19","first-page":"1480","article-title":"Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection","volume":"91","author":"Ozyilkan","year":"1996","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib20","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0168-8278(00)80065-3","article-title":"Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease","volume":"32","author":"Zein","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jfma.2025.10.044_bib21","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1743-422X-8-367","article-title":"Association of HCV with diabetes mellitus: an Egyptian case-control study","volume":"8","author":"Elhawary","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.jfma.2025.10.044_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/539361","article-title":"Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study","volume":"2013","author":"Memon","year":"2013","journal-title":"J Diabetes Res"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.044_bib23","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1136\/gut.2010.213553","article-title":"Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study","volume":"59","author":"Stepanova","year":"2010","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.jfma.2025.10.044_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J Viral Hepat"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.044_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among hemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/jhep.2003.50291","article-title":"Hepatitis C virus infection and incident type 2 diabetes","volume":"38","author":"Mehta","year":"2003","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.044_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1053\/j.ajkd.2013.03.037","article-title":"Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts","volume":"62","author":"Tseng","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12072-018-9915-5","article-title":"APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?","volume":"13","author":"Kanda","year":"2019","journal-title":"Hepatol Int"},{"issue":"15","key":"10.1016\/j.jfma.2025.10.044_bib30","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jfma.2025.10.044_bib31","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.14309\/ajg.0000000000001281","article-title":"Ledipasvir\/Sofosbuvir for 8, 12, or 24 weeks in hepatitis C patients undergoing dialysis for end-stage renal disease","volume":"116","author":"Chuang","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/v14020362","article-title":"The novel finding of dynamic change in eGFR up to one year after end of treatment in HCV-infected patients receiving Sofosbuvir and Velpatasvir","volume":"14","author":"Wu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jfma.2025.10.044_bib33","article-title":"The efficacy and safety of direct-acting antiviral regimens for end-stage renal disease patients with HCV infection: a systematic review and network meta-analysis","volume":"11","author":"Chen","year":"2023","journal-title":"Front Public Health"},{"issue":"3","key":"10.1016\/j.jfma.2025.10.044_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib35","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.cgh.2022.01.050","article-title":"Long-term evolution of estimated glomerular filtration rate in patients with antiviral treatment for hepatitis C virus infection","volume":"21","author":"Liu","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib36","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2337\/cd18-0112","article-title":"Success of direct-acting, antiviral-based therapy for chronic hepatitis C is not affected by type 2 diabetes","volume":"38","author":"Niccum","year":"2020","journal-title":"Clin Diabetes"},{"issue":"5","key":"10.1016\/j.jfma.2025.10.044_bib37","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/liv.13036","article-title":"Sofosbuvir-based regimens in clinical practice achieve SVR rates closer to clinical trials: results from ERCHIVES","volume":"36","author":"Butt","year":"2016","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib38","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1186\/s12902-022-01198-x","article-title":"HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus","volume":"22","author":"Angel","year":"2022","journal-title":"BMC Endocr Disord"},{"issue":"6","key":"10.1016\/j.jfma.2025.10.044_bib39","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jfma.2025.10.044_bib40","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jfma.2025.10.044_bib41","series-title":"Poster presentation 2103. The International Liver Congress 2021 (EASL)","article-title":"Changhua-integrated program to stop hepatitis C infection (CHIPS-C) of Taiwan","author":"Hu","year":"2021"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s12072-023-10605-x","article-title":"Planning, implementing, and evaluating Hepatitis C virus elimination via collaborative community-based care cascade: age-period-cohort model for estimating demand from antecedent anti-HCV survey","volume":"18","author":"Lin","year":"2024","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jfma.2025.10.044_bib43","series-title":"Poster presentation 1993. The international liver congress 2023 (EASL)","article-title":"Zero-HCV before end stage renal disease (ESRD). A collaborative \u201ctreat-all\u201d approach to eliminate HCV in chronic kidney disease population in Taiwan","author":"Hu","year":"2023"},{"issue":"2","key":"10.1016\/j.jfma.2025.10.044_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11020423","article-title":"Micro-elimination of hepatitis C among patients with kidney disease by using electronic reminder System-A hospital-based experience","volume":"11","author":"Su","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.jfma.2025.10.044_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112509","article-title":"Strategy for the micro-elimination of hepatitis C among patients with diabetes Mellitus-A hospital-based experience","volume":"10","author":"Su","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2025.10.044_bib46","unstructured":"Hu TH, Lim LS, Chang KC et al. HCV micro-elimination of diabetic population in a medical center. APASL 2023 Oral Present FPO3-13."},{"key":"10.1016\/j.jfma.2025.10.044_bib47","article-title":"Micro-elimination of hepatitis C (HCV) in a large and risky population of diabetic patients by collaborative care system","author":"Lin","year":"2025","journal-title":"AASLD"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib48","first-page":"65","article-title":"A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment","volume":"16","author":"Lee","year":"2010","journal-title":"Am J Manag Care"},{"issue":"Suppl 1","key":"10.1016\/j.jfma.2025.10.044_bib49","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.jfma.2021.12.016","article-title":"Achievements and challenges in chronic kidney disease care in Taiwan","volume":"121","author":"Hsu","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.jfma.2025.10.044_bib51","article-title":"Eliminating hepatitis C in Taiwan by 2025: strategies and progress","volume":"40","author":"Wu Grace","year":"2021","journal-title":"Taiwan J Public Health"},{"issue":"Suppl 3","key":"10.1016\/j.jfma.2025.10.044_bib52","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1093\/infdis\/jiad016","article-title":"Policy and strategy for hepatitis C virus elimination at the national level: experience in Taiwan","volume":"228","author":"Chien","year":"2023","journal-title":"J Infect Dis"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005893?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005893?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T15:58:04Z","timestamp":1766159884000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625005893"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"alternative-id":["S0929664625005893"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.044","relation":{},"ISSN":["0929-6646"],"issn-type":[{"type":"print","value":"0929-6646"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Micro-elimination of hepatitis C in patients with chronic kidney disease and diabetes in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.10.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}